Biocon and Mylan to Collaborate in Generic Biologics

Mylan (Canonsburg, PA) says it has signed an agreement with biotechnology firm Biocon (Bangalore, India) for an exclusive collaboration for the development, manufacturing, and commercialization of multiple, high-value generic biologic compounds for the global market. Mazumdar-Shaw: To lower healthcare costs. The generic pharmaceutical industry, which is based almost entirely on chemically synthesized drugs, is poised for change, Biocon says. Governments worldwide are trying to facilitate the entry of generic biotech or protein derived drugs, in an effort to lower...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers